AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 7636643
Drug: Zinc supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplementation (3 mg of Zn acetate per day)
Trial: 2539764
Drug: Nedocromil (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nedocromil (2 puffs of 2 mg/puff)
Trial: 911607
Drug: Warning labels
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warning labels showing drugs known to interact
Trial: 30341969
Drug: Conventional dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional dosing of PPI
Trial: 30341969
Drug: Genotype-guided dosing
RxNorm normalized name: dengue virus live antigen, CYD serotype 1 / dengue virus live antigen, CYD serotype 2 / dengue virus live antigen, CYD serotype 3 / dengue virus live antigen, CYD serotype 4 Injection [Dengvaxia]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Genotype-guided dosing of PPI
Trial: 27465372
Drug: 0 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 g fiber from SCF/d
Trial: 25660414
Drug: Amino acid
RxNorm normalized name: Amino Acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amino acid supplementation twice daily
Trial: 25660414
Drug: Placebo supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo supplementation twice daily
Trial: 18684664
Drug: Optimal pharmacological
RxNorm normalized name: Optima Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimal pharmacological treatment
Trial: 12816824
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate (0.05% cream or 0.005% ointment) applied twice weekly
Trial: 12816824
Drug: Emollient alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emollient alone (placebo) applied twice weekly
Trial: 12816824
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate cream applied twice weekly
Trial: 9254261
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no perftoran infusion)
Trial: 3297907
Drug: Paracentesis (4-6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracentesis (4-6 L/day until disappearance of ascites) and intravenous albumin infusion (40 g after each tap)
Trial: 29231409
Drug: Acupoint injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupoint injection of salmon calcitonin (100 U, 4 mL total, 1 mL per acupoint)
Trial: 29231409
Drug: Intramuscular injection
RxNorm normalized name: rabies, intramuscular injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injection of salmon calcitonin (100 U)
Trial: 29231409
Drug: Blank group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blank group (0.9% sodium chloride injection, 1 mL per acupoint)
Trial: 7926494
Drug: Omeprazole 10
RxNorm normalized name: omeprazole 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 10 mg once daily
Trial: 16868803
Drug: Omeprazole 10
RxNorm normalized name: omeprazole 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 10 mg or 20 mg
Trial: 27296366
Drug: Group-based outpatient
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group-based outpatient physiotherapy intervention (1-hour class weekly for 6 weeks)
Trial: 18703875
Drug: Evidence-based algorithm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evidence-based algorithm treatment
Trial: 18703875
Drug: Algorithm treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Algorithm treatment
Trial: 16462914
Drug: Rofecoxib (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rofecoxib (50 mg, daily)
Trial: 16462914
Drug: Tramadol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol (50 mg, 3 times per day)
Trial: 10872103
Drug: Generic pentoxifylline
RxNorm normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Generic pentoxifylline sustained-release (SR) tablet
Trial: 8803512
Drug: Glutamine (Group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glutamine (Group G)
Trial: 19240374
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose Th221 (60 mg/day)
Trial: 19240374
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose Th221 (20.4 mg/day)
Trial: 17960962
Drug: Risperidone 3
RxNorm normalized name: risperidone 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone 3 mg b.i.d.
Trial: 15909856
Drug: Regimen I
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen I (standard high dose regimen) - 100 ml ASV loading dose followed by 50 ml every six hours
Trial: 15909856
Drug: Regimen II
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen II - 30 ml ASV loading dose followed by 30 ml continuous infusion every six hours
Trial: 9585823
Drug: OM-85-BV (3.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OM-85-BV (3.5 mg of bacterial extracts)
Trial: 23791153
Drug: Sublingual misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sublingual misoprostol (800 μg)
Trial: 14572570
Drug: Relaxation Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Relaxation Therapy
Trial: 11084571
Drug: Long-term oral
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term oral contraceptive use
Trial: 30144429
Drug: Obeticholic Acid
RxNorm normalized name: Obeticholic acid
DrugBank: Obeticholic acid (DB05990)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Obeticholic Acid (OCA) 10 mg/kg for 2 weeks in mice
Trial: 26563519
Drug: Topical recombinant
RxNorm normalized name: thrombin topical recombinant 5000 intl units topical powder for reconstitution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical recombinant human epidermal growth factor (EGF) cream
Trial: 12722031
Drug: Low-dose prednisolone
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose prednisolone therapy (initial dose of 20 mg/d, tapered to 5 mg/d over 2 years)
Trial: 22616078
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no steroid treatment)
Trial: 12722031
Drug: Low-dose prednisolone
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose prednisolone therapy
Trial: 8979658
Drug: Timolol maleate
RxNorm normalized name: Timolol Maleate
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Timolol maleate in solution (TS) 0.5 percent
Trial: 6393316
Drug: Cimetidine (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (800 mg daily intravenously for 2 days, then 1000 mg daily orally for 10 days in divided doses)
Trial: 28214596
Drug: certolizumab pegol
RxNorm normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: certolizumab pegol (400 mg qd reduced to 200 mg qd after one month)
Trial: 24823623
Drug: Zoster vaccine
RxNorm normalized name: ZOSTER VACCINE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zoster vaccine (ZV; Zostavax; Merck)
Trial: 22901348
Drug: Duloxetine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine (30 mg/d, increased to a maximum of 120 mg/d)
Trial: 18541798
Drug: 75 g
RxNorm normalized name: Zosyn 3.375 GM Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 g of sucrose 40 minutes before exercise
Trial: 18541798
Drug: 37 g
RxNorm normalized name: BENZALKONIUM CHLORIDE 0.37 g in 100 g TOPICAL LIQUID [YOOLOGY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 37 g of sucrose 5 minutes before exercise
Trial: 2186237
Drug: Oral corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral corticosteroids (30 mg of prednisone or greater)
Trial: 21876310
Drug: Cloxacillin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cloxacillin (100 mg/mL) plus heparin (1000 IU/mL) as a 2.5-mL solution instilled in each catheter lumen after dialysis session
Trial: 10344062
Drug: Perindopril 2
RxNorm normalized name: perindopril 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perindopril 2 mg
Trial: 8110556
Drug: Transdermal hyoscine
RxNorm normalized name: HYOSCINE HYDROBROMIDE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal hyoscine (loading dose 140 micrograms, followed by 5 micrograms h‐1)
Trial: 24330906
Drug: Transcranial direct
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcranial direct current stimulation (tDCS) delivered at 1-3 mA current intensity for 20-30 minutes in once- to twice-daily sessions for up to 3 years
Trial: 19423455
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment plus low molecular weight heparin (LMWH) treatment (LT group, n = 135)
Trial: 7831140
Drug: 0.3 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg/kg oral midazolam
Trial: 3365924
Drug: Controlled-release intravenous
RxNorm normalized name: Afeditab CR
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Controlled-release intravenous infusion system (CRIS) with 20 mL of D5NS as the diluent
Trial: 3365924
Drug: Controlled-release intravenous
RxNorm normalized name: Afeditab CR
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Controlled-release intravenous infusion system (CRIS) with 10 mL of 5% dextrose and 0.9% sodium chloride injection (D5NS)
Trial: 30100096
Drug: Physical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical therapy for low back pain with or without manual therapy and exercise directed at the femoroacetabular joints
Trial: 30100096
Drug: Having a
RxNorm normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Having a concurrent hip problem
Trial: 26959198
Drug: Low-dose aspirin
RxNorm normalized name: low-dose aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose aspirin (81 mg, n=615)
Trial: 20859299
Drug: Tocotrienol-rich fraction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tocotrienol-rich fraction (TRF) 400 mg daily
Trial: 18060999
Drug: Prophylactic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic treatment for atrial fibrillation
Trial: 8080680
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy (cyclophosphamide, doxorubicin, 5‐fluorouracil)
Trial: 2925456
Drug: Ceftriaxone (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone (1 g, intravenous administration, 30 to 60 minutes preoperatively)
Trial: 26192876
Drug: Control (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (standard recombinant FSH/GnRH antagonist protocol)
Trial: 15611423
Drug: Oral PUVA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral PUVA using methoxsalen capsules and a portable tanning unit at home
Trial: 31300493
Drug: NRT patches
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NRT patches
Trial: 27795779
Drug: bupivacaine 0.25%
RxNorm normalized name: BUPIVACAINE 0.25%/NS INJ 400ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bupivacaine 0.25% (1 ml/kg) with fentanyl 1 μg/kg and clonidine 1μg/kg (group I)
Trial: 27795779
Drug: bupivacaine 0.25%
RxNorm normalized name: BUPIVACAINE 0.25%/NS INJ 400ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bupivacaine 0.25% (1 ml/kg) with fentanyl 1 μg/kg (group II)
Trial: 20723260
Drug: Fesoterodine 4
RxNorm normalized name: fesoterodine 4 mg oral tablet, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fesoterodine 4 mg
Trial: 9410299
Drug: Budesonide (Pulmicort
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide (Pulmicort and Horacort) 640 mg or 800 mg daily for 6 weeks
Trial: 8408569
Drug: High-titer vaccine
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-titer vaccine (10^6 PFU)
Trial: 8408569
Drug: Low-titer vaccine
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-titer vaccine (10^5 PFU)
Trial: 31353941
Drug: Scapular exercise
RxNorm normalized name: Haemophilus capsular oligosaccharide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scapular exercise programme plus physical therapy treatment
Trial: 26704923
Drug: 80 μg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 μg/day Vitamin D3 dissolved in oil
Trial: 21663811
Drug: GlideScope (G)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GlideScope (G)
Trial: 2344752
Drug: Kinetic Treatment
RxNorm normalized name: Kineticream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kinetic Treatment Table (KTT)
Trial: 6108449
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no aminoacid therapy)
Trial: 17288990
Drug: Narrative Exposure
RxNorm normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Narrative Exposure Therapy (NET), 5 sessions
Trial: 9433650
Drug: Single oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral administration of grepafloxacin (200 to 1200 mg)
Trial: 9433650
Drug: Repeat oral
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeat oral administration of grepafloxacin (400 and 800 mg)
Trial: 3786346
Drug: Nicotine chewing
RxNorm normalized name: nicotine Chewing Gum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine chewing gum (2 mg)
Trial: 27933408
Drug: PRO +
RxNorm normalized name: Climara Pro
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PRO + PRT (0.33 g/kg body mass of a milk-based protein matrix for 12 weeks)
Trial: 27933408
Drug: PRO (0.33
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRO (0.33 g/kg body mass of a milk-based protein matrix for 12 weeks)
Trial: 21226674
Drug: Occupational therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Occupational therapy group
Trial: 15002680
Drug: Referral to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Referral to mental health treatment
Trial: 15002680
Drug: Referral rates
RxNorm normalized name: teferrol
DrugBank: Iron polymaltose (DB15763)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Referral rates to substance abuse and mental health treatment
Trial: 3234475
Drug: Alcoholic oral
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alcoholic oral solution (12 mg)
Trial: 3234475
Drug: Tablets (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets (12 mg)
Trial: 28038865
Drug: Pegfilgrastim (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegfilgrastim (6 mg administered ∼24 hours after chemotherapy plus bevacizumab every 14 days for 4 cycles, with the option to continue for ≤ 60 months)
Trial: 28038865
Drug: Placebo (administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (administered ∼24 hours after chemotherapy plus bevacizumab every 14 days for 4 cycles, with the option to continue for ≤ 60 months)
Trial: 23907740
Drug: Ceftaroline fosamil
RxNorm normalized name: Ceftaroline fosamil
DrugBank: Ceftaroline fosamil (DB06590)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ceftaroline fosamil 600 mg IV over 1 hour q12h for ABSSSI and CABP patients
Trial: 23907740
Drug: Ceftaroline fosamil
RxNorm normalized name: Ceftaroline fosamil
DrugBank: Ceftaroline fosamil (DB06590)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ceftaroline fosamil 50-2000 mg IV infusion over 1 hour or IM injection q12h or q24h for healthy subjects
Trial: 19860230
Drug: Propofol (0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (0.75 mg x kg(‐1)) and Suxamethonium (1.2 mg x kg(‐1))
Trial: 15583914
Drug: SPECT measurements
RxNorm normalized name: spelt seed extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPECT measurements of dopamine D2-like receptors (D2) using 123I‐epidepride in patients
Trial: 9211474
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg proglumide
Trial: 9211474
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg proglumide
Trial: 9211474
Drug: 0.05 mg
RxNorm normalized name: biotin 0.05 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05 mg proglumide
Trial: 2970220
Drug: Group 1
RxNorm normalized name: Chlamydophila psittaci biogroup 1 Ab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 1 physicians received general information about vaccine decisions; specific outcome not detailed.
Trial: 14714360
Drug: Tripterygium polyglycosides
RxNorm normalized name: Tripterygium wilfordii whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tripterygium polyglycosides tablet and composite Salviae tablet (Control)
Trial: 2048660
Drug: Intravenous diamorphine
RxNorm normalized name: Diamorphine
DrugBank: Diamorphine (DB01452)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous diamorphine 0.5 mg/hour as a supplement to extradural bupivacaine (0.125% at 15 ml/hour)
Trial: 2048660
Drug: Extradural diamorphine
RxNorm normalized name: Diamorphine
DrugBank: Diamorphine (DB01452)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extradural diamorphine 0.5 mg/hour as a supplement to extradural bupivacaine (0.125% at 15 ml/hour)
Trial: 9125
Drug: Atropine 0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atropine 0.6 mg
Trial: 7272153
Drug: Glycopyrrolate 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycopyrrolate 0.3 mg or 0.2 mg
Trial: 15681941
Drug: 5-ml saline
RxNorm normalized name: sodium chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5-ml saline injection
Trial: 15681941
Drug: 10-ml saline
RxNorm normalized name: sodium chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10-ml saline injection
Trial: 15681941
Drug: 15-ml saline
RxNorm normalized name: FENTANYL 2MCG/ROPIV 0.15%/ML NS 250ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15-ml saline injection
Trial: 15681941
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no saline injection)
Trial: 2906171
Drug: Norfloxacin 400
RxNorm normalized name: norfloxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norfloxacin 400 mg twice daily for 7 days
Trial: 1817630
Drug: Priming dose
RxNorm normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Priming dose of pancuronium (10 micrograms kg‐1)
Trial: 6127172
Drug: Acebutolol (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acebutolol (1 mg/kg i.v. during the first 2 days followed by a daily oral dose of 600 mg for 3 weeks)
Trial: 28385440
Drug: Implant-retained fixed
RxNorm normalized name: betaine
DrugBank: Betaine (DB06756)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Implant-retained fixed metal-acrylic resin prostheses
Trial: 9650870
Drug: Antibiotic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic therapy plus scaling (group 2)
Trial: 9650870
Drug: Placebo therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo therapy plus scaling (group 4)
Trial: 9650870
Drug: Placebo therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo therapy but no scaling (group 3)
Trial: 9650870
Drug: Systemic administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Systemic administration of metronidazole plus amoxicillin
Trial: 2651328
Drug: Atenolol (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol (100 mg) alone
Trial: 2651328
Drug: Atenolol (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol (100 mg) and nifedipine (20 mg)
Trial: 2651328
Drug: Atenolol (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol (100 mg) and nicardipine (40 mg)
Trial: 406634
Drug: Methadone (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methadone (up to 10 mg)
Trial: 15485290
Drug: 12-dose WHO
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12-dose WHO multi-drug therapy (Group 1, 128 patients)
Trial: 15485290
Drug: 24-dose WHO
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 24-dose WHO multi-drug therapy (Group 2, 85 patients)
Trial: 4020569
Drug: Cholestyramine 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholestyramine 2 g four times daily
Trial: 7818005
Drug: Ursodiol 600
RxNorm normalized name: ursodeoxycholate
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursodiol 600 mg
Trial: 31429974
Drug: 8-week smartphone-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8-week smartphone-based aftercare intervention (German version of 'Recovery Record') with therapist feedback as an adjunct to treatment as usual